The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $37.77, representing a -0.03% change from its previous close.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $80 from $86 and keeps a Buy rating on the shares. While Q1 earnings ...

The prospects for a one-time treatment that reduces the risk of heart disease for the rest of a person’s life just got ...

EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to deliver better RNA at scale, today ...

The North America CRISPR gene editing market is poised for substantial growth, with projections indicating a robust annual expansion of 24.4% throughout the forecast period. By 2031, it is anticipated ...

The CRISPR gene editing technology has revolutionized the field of molecular biology, offering unprecedented precision and efficiency in genetic manipulation. With its vast potential in various ...

With tariffs pushing manufacturing home to the U.S., Pitchbook warns of reduced M&A activity and venture capital funding.

Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended ...

The incidence of Human Papillomavirus (HPV)–associated oropharyngeal cancers—tumors of the back of the mouth and throat—is ...

Scientists at the University of California, Riverside, have discovered how adult stem cells retain their regenerative power.